ROP21

ROP21 is a Toxoplasma gondii rhoptry-family protein that localizes to the parasitophorous vacuole and the cyst matrix, reaching these compartments not through classical microneme, rhoptry, or dense granule secretion but via small vesicles consistent with a constitutive secretory pathway (PMID:27450947). Functionally, ROP21 acts redundantly with ROP17: single deletion leaves in vitro growth and bradyzoite differentiation intact, whereas combined ∆rop21/∆rop17 loss reduces tissue cyst burden by roughly half during chronic infection, implicating ROP21 in the establishment or maintenance of cysts in vivo (PMID:27450947). ROP21 is dispensable for the antitumor immunity elicited by uracil-auxotrophic T. gondii vaccine strains (PMID:27447180). Beyond its localization and redundant contribution to cyst burden, no detailed enzymatic mechanism or substrate has been characterized in the available corpus.

1. 2016 Medium

   Establishing where ROP21 goes and how it gets there addressed whether it is a canonical secreted effector; it instead traffics via a non-classical vesicular route to the vacuole and cyst matrix, distinguishing it from typical rhoptry/dense-granule effectors.

   Evidence CRISPR/Cas9 C-terminal epitope tagging and localization imaging in T. gondii Pru

   PMID:27450947

   Open questions at the time

   • Trafficking machinery routing ROP21 through the constitutive pathway is unidentified
   • No molecular partner at the PVM or cyst matrix defined
   • Single-lab localization in one strain
2. 2016 Medium

   Genetic deletion tested whether ROP21 is required for parasite fitness; it is dispensable in vitro and for differentiation but contributes redundantly with ROP17 to in vivo cyst burden, defining a chronic-infection role.

   Evidence CRISPR/Cas9 single and double (∆rop21/∆rop17) knockouts with in vitro growth/differentiation assays and in vivo mouse cyst quantification in T. gondii Pru

   PMID:27450947

   Open questions at the time

   • The molecular basis of the redundancy with ROP17 is unknown
   • Whether ROP21 acts on host or parasite targets during cyst formation is undetermined
   • Single-lab in vivo readout
3. 2016 Medium

   Deletion in a vaccine-strain background tested whether ROP21 is needed for parasite-driven immunotherapy; it is not, showing the antitumor immune response does not depend on this PVM protein.

   Evidence Targeted deletion in Δku80 uracil-auxotroph vaccine strain with in vivo antitumor efficacy assay

   PMID:27447180

   Open questions at the time

   • Does not address a role in natural infection immunity
   • Negative/dispensability result gives no positive function
   • Strain background not specified beyond Δku80 vaccine strain
4. 2025 Low

   The question of ROP21's biochemical activity was addressed by asserting it phosphorylates protein substrates, positioning it as an active kinase rather than a pseudokinase.

   Evidence Property stated in a vaccine-design context without a described in vitro kinase assay

   PMID:39855488

   Open questions at the time

   • No in vitro kinase assay or substrate identified in the source
   • Annotation-level claim not backed by direct enzymology
   • Cannot distinguish active kinase from pseudokinase experimentally

• The direct substrate(s), the trafficking machinery for its constitutive secretion, and the molecular basis of its redundancy with ROP17 remain unresolved.
• No validated phosphorylation substrate
• No identified receptor/machinery for vesicular delivery to the PVM and cyst matrix
• Mechanism of the cyst-burden phenotype uncharacterized